Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 17/20 | 0.43 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | XIAP | P98170 | 1/20 | 0.41 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10193707 | 0.90 | PDE4D (0.42) | BACE1PDE4D | |
| SCHEMBL10193220 | 0.87 | SMN1; SMN2 (0.49) | BACE1 | |
| SCHEMBL10192934 | 0.86 | BACE1 (0.45) | BACE1BACE2 | |
| SCHEMBL10192951 | 0.86 | BACE1 (0.48) | BACE1BACE2 | |
| SCHEMBL10193944 | 0.86 | KDM4E (0.43) | BACE1BACE2XIAPBIRC2 | |
| SCHEMBL10193947 | 0.84 | BACE1 (0.41) | BACE1BACE2 | |
| SCHEMBL10194907 | 0.77 | SMN1; SMN2 (0.38) | PDE4D | |
| SCHEMBL10194914 | 0.76 | ALDH1A1 (0.43) | BACE1 | |
| SCHEMBL10192941 | 0.74 | BACE1 (0.44) | BACE1BACE2 | |
| SCHEMBL10193706 | 0.73 | NPC1 (0.39) | BACE1BACE2PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015961-A1 | ISOTHIOUREA DERIVATIVES OR ISOUREA DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015961-A1 | ISOTHIOUREA DERIVATIVES OR ISOUREA DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | BACE1, BACE2, APP | BACE1 1/4885BACE2 2/4885PDE4D 3891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.